Cargando…

Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19

Patients with COVID-19 who are admitted to intensive care unit (ICU) are at high risk of developing secondary infections, including invasive fungal infections such as invasive pulmonary aspergillosis (IPA). The main purpose was to analyse the putative COVID-19 Associated Pulmonary Aspergillosis (CAP...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Martín, C., Madrid Martínez, E., González Pellicer, R., Armero Ibáñez, R., Martínez González, E., Llau Pitarch, J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Published by Elsevier España, S.L.U. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057739/
https://www.ncbi.nlm.nih.gov/pubmed/33994593
http://dx.doi.org/10.1016/j.redar.2021.02.012
_version_ 1783680887453384704
author Sánchez Martín, C.
Madrid Martínez, E.
González Pellicer, R.
Armero Ibáñez, R.
Martínez González, E.
Llau Pitarch, J.V.
author_facet Sánchez Martín, C.
Madrid Martínez, E.
González Pellicer, R.
Armero Ibáñez, R.
Martínez González, E.
Llau Pitarch, J.V.
author_sort Sánchez Martín, C.
collection PubMed
description Patients with COVID-19 who are admitted to intensive care unit (ICU) are at high risk of developing secondary infections, including invasive fungal infections such as invasive pulmonary aspergillosis (IPA). The main purpose was to analyse the putative COVID-19 Associated Pulmonary Aspergillosis (CAPA) patients in our setting. In these patients, we performed mycological culture in bronchoalveolar lavage (BAL) for isolation of Aspergillus sp. We followed the AspICU algorithm to diagnose putative IPA. Moreover, we considered relevant the positivity of galactomannan in BAL. We diagnosed putative IPA in 3 patients. The common features of these 3 patients were: more than 21 days of stay in ICU, severe acute respiratory distress syndrome (ARDS) and treatment with steroids (1 mg/kg per day). Therefore, CAPA has to be systematically considered although a new algorithm to diagnose it is needed to treat patients in early stages in order to avoid catastrophic outcomes.
format Online
Article
Text
id pubmed-8057739
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-80577392021-04-21 Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19 Sánchez Martín, C. Madrid Martínez, E. González Pellicer, R. Armero Ibáñez, R. Martínez González, E. Llau Pitarch, J.V. Rev Esp Anestesiol Reanim Caso Clínico Patients with COVID-19 who are admitted to intensive care unit (ICU) are at high risk of developing secondary infections, including invasive fungal infections such as invasive pulmonary aspergillosis (IPA). The main purpose was to analyse the putative COVID-19 Associated Pulmonary Aspergillosis (CAPA) patients in our setting. In these patients, we performed mycological culture in bronchoalveolar lavage (BAL) for isolation of Aspergillus sp. We followed the AspICU algorithm to diagnose putative IPA. Moreover, we considered relevant the positivity of galactomannan in BAL. We diagnosed putative IPA in 3 patients. The common features of these 3 patients were: more than 21 days of stay in ICU, severe acute respiratory distress syndrome (ARDS) and treatment with steroids (1 mg/kg per day). Therefore, CAPA has to be systematically considered although a new algorithm to diagnose it is needed to treat patients in early stages in order to avoid catastrophic outcomes. Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Published by Elsevier España, S.L.U. 2022-01 2021-04-20 /pmc/articles/PMC8057739/ /pubmed/33994593 http://dx.doi.org/10.1016/j.redar.2021.02.012 Text en © 2021 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Caso Clínico
Sánchez Martín, C.
Madrid Martínez, E.
González Pellicer, R.
Armero Ibáñez, R.
Martínez González, E.
Llau Pitarch, J.V.
Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title_full Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title_fullStr Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title_full_unstemmed Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title_short Aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por COVID-19
title_sort aspergilosis pulmonar invasiva en pacientes con síndrome de distrés respiratorio por covid-19
topic Caso Clínico
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057739/
https://www.ncbi.nlm.nih.gov/pubmed/33994593
http://dx.doi.org/10.1016/j.redar.2021.02.012
work_keys_str_mv AT sanchezmartinc aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19
AT madridmartineze aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19
AT gonzalezpellicerr aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19
AT armeroibanezr aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19
AT martinezgonzaleze aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19
AT llaupitarchjv aspergilosispulmonarinvasivaenpacientesconsindromededistresrespiratorioporcovid19